期刊文献+

表皮生长因子受体酪氨酸激酶抑制剂治疗老年晚期非小细胞肺癌临床分析 被引量:1

Epidermal growth factor receptor tyrosine kinase inhibitor in treatment of elderly patients with non-small-cell lung cancer
原文传递
导出
摘要 对2006年2月至2010年9月收治的70例年龄≥65岁接受厄洛替尼或吉非替尼治疗的晚期非小细胞肺癌患者的疗效及安全性进行回顾性分析。总有效率31.4%(22/70),控制率84.3%(59/70),中位无进展生存期8.0个月,中位生存期13.5个月(P〈0.05),1年生存率54.3%(38/70);女性的有效率(42.8%)和控制率(94.3%)优于男性(20.0%和74.3%)(P〈0.05),非吸烟和体力状况〈2分者预后好;不良反应主要为轻度皮疹及腹泻。 Seventy patients with advanced non-small-cell lung cancer (NSCLC) aged 65 or above were treated with epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) erlotinib or gefitinibfrom February 2006 to September 2010. The efficacy and toxicities of treatment were retrospectively analyzed. The overall response rate and disease control rate were 31.4% and 84. 3% , respectively. The median progression-free survival time and median survival time were 8.0 months and 13.5 months, respectively(P 〈 0. 05 ). One-year survival rate was 54. 3%. Response rate ( CR + PR) (42.9%) and disease control rate(94. 3% ) in female patients were superior to males ( 20.0% and 74. 3% ) ( P 〈 0. 05 ). Non-smoking and PS score 〈 2 were good predictors for survival. The side effects were generally mild and mainly were skin rash and diarrhea.
出处 《中华全科医师杂志》 2012年第3期221-223,共3页 Chinese Journal of General Practitioners
关键词 非小细胞肺 受体 表皮生长因子酪氨酸激酶抑制剂 Carcinoma non-small-cell lung Receptor,epidermal growth factor
  • 相关文献

参考文献11

  • 1Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1 ). Eur J Cancer,2009,45:261-267.
  • 2Chen KY, Chen JH, Shih JY, et al. Octogenarians with advanced non-small cell lung cancer: treatment modalities, survival, and prognostic factors. J Thorac Oncol, 2010,5 : 82 -89.
  • 3Shepherd FA, Rndrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005,353:123-132.
  • 4Parra HS, Cavina R, Latteri F, et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib ( ' Iressa' , ZD1839) in non-small-cell lung cancer. Br J Cancer,2004,91 : 208-212.
  • 5Ebi N, Semba H, Tokunaga SJ, et al. A phase II trial of gefitinib monotherapy in chemotherapy-naive patients of 75 years or older with advanced non-small cell lung cancer. J Thorac Oncol, 2008, 3: 1166-1171.
  • 6Hotta K, Ueoka H, Kiura K, et al. Safety and efficacy of gefitinih treatment in elderly patients with non-small-cell lung cancer: Okayama lung cancer study group experience. Acta Oncol, 2005, 44:717-722.
  • 7Pemg RP, Yang CH, Chert YM, et al. High efficacy of erlotinib in Taiwan Residents NSCLC patients in an expanded access program study previously treated with chemotherapy. Lung Cancer, 2008,62:78- 84.
  • 8Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: fesuhs from a randomised, placebo-controlled, muhicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet, 2005, 366 : 1527-1537.
  • 9Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced non-small-cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR. 21. J Clin Oncol,2008, 26:2350-2357.
  • 10Mok TS, Wu YL, Thongprasert S,et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361:947-957.

二级参考文献14

  • 1王金万,孙燕,刘永煜,于起涛,张沂平,李凯,朱允中,周清华,侯梅,管忠震,李维廉,庄武,王东林,梁后杰,秦凤展,卢辉山,刘晓晴,孙红,张燕军,王杰军,罗素霞,杨瑞合,涂远荣,王秀问,宋恕平,周静敏,游丽芬,王竞,姚晨.重组人血管内皮抑素联合NP方案治疗晚期NSCLC随机、双盲、对照、多中心Ⅲ期临床研究[J].中国肺癌杂志,2005,8(4):283-290. 被引量:626
  • 2张力,王淑兰,张晓彤,李龙芸,王孟昭.吉非替尼单药治疗老年晚期非小细胞肺癌患者的临床观察[J].中华内科杂志,2007,46(5):392-395. 被引量:10
  • 3Owonikoko TK, gagin CC, Belani CP, et al. Lung cancer in elderly patieats: an analysis of the surveillance, epidemiolog)5 and end results database. J Clin Oncol, 2007, 25 (35): 5570- 5577.
  • 4Jackman DM, Yeap BY, Lindeman NI, et al. Phase II clinical trial of chemo- therapy-naive patients > or = 70 years of age treated with erlotinib for ad- vanced non-small-celllung cancer.J Clin Oncol, 2007, 25(7): 760-766.
  • 5Ebi N, Semba H, Tokunaga SJ, et al. A phase II trial of gefitinib monotherapy in chemotherapy-naive patients of 7S years or older with advanced non-small cell lung cancer.J Thorac Oncol, 2008, 3(10): 1166-1171.
  • 6Crino L, Cappuzzo F, Zafloukal P, et al. Gefitinib versus vinorelbine in chemotherapy-naive elderly patients with advanced non-small-cell lung cancer (INVITE): a randomized, phase II study. J Clin Oncol, 2008, 26(26): 4253-4260.
  • 7Ramalingam SS, Dahlberg SE, Langer CJ, et al. Outcomes for elderly, advanced-stage non small-cell lung cancer patients treated with bevacizumab in combination with carboplatin and paclitaxel: analysis of Eastern Cooperative Oncology Group Trial 4599. J Clin Oncol, 2008, 26( 1): 60-65.
  • 8Wheatley-Price P, Ding K, Seymour L, et al. Erlotinib for advanced non-small- cell lung cancer in the elderly: an analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol, 2008, 26(14): 2350-2357.
  • 9Hotta K, Ueoka H, Kiura K, et al. Safety and efficacy of gefitinib treatment in elderly patients with non-small-cell lung cancer: Okayama Lung Cancer Study Group experience. Acta Oncol, 2005, 44(7): 717-722.
  • 10Socinski MA, Novello S, Brahmer JR, et al. Multicenter, phase II trial of suni- tinib in previously treated, advanced non-small-cell lung cancer.J Clin Oncol, 2008, 26(4): 650-656.

共引文献6

同被引文献51

引证文献1

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部